Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) EPS (Weighted Average and Diluted) (2020 - 2025)

vTv Therapeutics' EPS (Weighted Average and Diluted) history spans 6 years, with the latest figure at -$0.43 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 26.47% year-over-year to -$0.43; the TTM value through Dec 2025 reached -$3.2, changed 0.0%, while the annual FY2025 figure was -$3.2, 0.0% changed from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.43 at vTv Therapeutics, up from -$1.08 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.01 in Q2 2021 and bottomed at -$9.78 in Q4 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.81 (2024), against an average of -$1.47.
  • The largest annual shift saw EPS (Weighted Average and Diluted) crashed 13305.56% in 2021 before it surged 82.92% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$4.5 in 2021, then tumbled by 117.24% to -$9.78 in 2022, then soared by 82.92% to -$1.67 in 2023, then surged by 79.64% to -$0.34 in 2024, then fell by 26.47% to -$0.43 in 2025.
  • Per Business Quant, the three most recent readings for VTVT's EPS (Weighted Average and Diluted) are -$0.43 (Q4 2025), -$1.08 (Q3 2025), and -$0.92 (Q2 2025).